NJ
Nitin B. Jain
Highly rated in
8
conditions
Highly rated in
8
conditions
Check Dr. Nitin B. Jain's experience treating your condition:
About Dr. Nitin B. Jain

Nitin Jain is an Interventional Radiologist and a Radiologist in Warren, Michigan. Jain has been practicing medicine for over 20 years and is highly rated in 8 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia ALL, Small Lymphocytic Lymphoma SLL, Pleural Effusion, Bone Marrow Aspiration, and Liver Embolization. He is licensed to treat patients in Michigan. Jain is currently accepting new patients.

His clinical research consists of co-authoring 368 peer reviewed articles and participating in 25 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Nitin B. Jain it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Nitin B. Jain accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter

Call to see if your plan is accepted.
Locations
11800 Twelve Mile Rd, Warren, MI 48093
Background & Education
Graduate Institution
University College Of Medicine, 2002
Specialties
Interventional Radiology
Radiology
Licenses
Diagnostic Radiology in MI
Hospital Affiliations
Ascension Macomb-Oakland Hospital - Madison Heights Campus
Ascension Macomb-Oakland Hospital - Warren Campus
Ascension St John Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


25 Clinical Trials

A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN Study
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Urelumab (CD137 mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears
A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia
Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears: A Multicenter Randomized Controlled Pragmatic Trial
Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
View 16 Less Clinical Trials -

368 Total Publications

CLL-162 PTX3 is Constitutively Active in CLL Cells.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors